Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Aeterna Zentaris Enters into Agreement with EMD Serono 14
Aeterna Zentaris Enters into Co-Promotion Agreement with Ascend Therapeutics for EstroGel and Macrilen 15
Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 16
Licensing Agreements 17
Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 17
Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 18
Rafa Labs Enters into Licensing Agreement with Aeterna Zentaris 19
Orient EuroPharma Enters into Licensing Agreement with Aeterna Zentaris 20
Aeterna Zentaris Enters into Option Agreement to License AEZS-120 Product 21
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 22
Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 23
Equity Offering 24
Aeterna Zentaris Plans to Raise up to USD50 Million in Public Offering of Shares 24
Aeterna Zentaris Raises USD7.6 Million in Private Placement of Units 25
Aeterna Zentaris Raises USD16.7 Million in Public Offering of Shares and Warrants 26
Aeterna Zentaris Raises USD37 Million in Public Offering of Shares and Warrants 28
Aeterna Zentaris Files Registration Statement For Public Offering Of Shares For US$50 Million 30
Aeterna Zentaris Completes Public Offering Of Units For US$13.2 Million 31
AEterna Zentaris Completes Public Offering Of Units For US$15 Million 32
AEterna Zentaris Completes Private Placement Of Units For US$7.8 Million 34
AEterna Zentaris Announces Public Offering Of Shares For US$4.6 Million 35
Aeterna Zentaris Completes Public Offering Of Units For US$17 Million 36
Aeterna Zentaris Completes Second Tranche Of Public Offering Of Common Stock For US$2 Million 37
Aeterna Zentaris Inc – Key Competitors 38
Aeterna Zentaris Inc – Key Employees 39
Aeterna Zentaris Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Nov 06, 2018: Aeterna Zentaris reports third quarter 2018 financial and operating results 41
Aug 09, 2018: Aeterna Zentaris reports second quarter 2018 financial and operating results 42
May 07, 2018: Aeterna Zentaris Reports First Quarter 2018 Financial and Operating Results 43
Mar 28, 2018: Aeterna Zentaris Announces Fourth Quarter And Full-Year 2017 Financial Results 45
Nov 08, 2017: Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results 48
Aug 10, 2017: Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results 50
May 08, 2017: Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results 53
Mar 15, 2017: Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results 55
Corporate Communications 57
Sep 25, 2018: Aeterna Zentaris names Leslie Auld as Chief Financial Officer 57
Mar 05, 2018: Aeterna Zentaris Names James Clavijo As Chief Financial Officer 58
Dec 08, 2017: Aeterna Zentaris Announces Departure of Interim Chief Financial Officer 59
Sep 25, 2017: Aeterna Zentaris Announces Appointment of Interim Chief Financial Officer 60
Sep 01, 2017: Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer 61
Legal and Regulatory 62
Dec 22, 2017: Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore 62
Dec 21, 2017: David Dodd and Philip Theodore respond to claim by Aeterna Zentaris 63
Product News 64
12/20/2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency 64
03/05/2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit 65
Product Approvals 66
Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency 66
Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date 67
Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults 68
Mar 30, 2017: Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017 69
Mar 07, 2017: Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen 70
Clinical Trials 71
May 01, 2017: Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex Did Not Achieve its Primary Endpoint 71
Apr 28, 2017: Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex 72
Mar 02, 2017: Aeterna Zentaris Announces Presentation Regarding Macrilen at 99th Annual Meeting of the Endocrine Society 73
Feb 14, 2017: Aeterna Zentaris Announces Zoptrex Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium 74
Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen 75
Jan 30, 2017: Aeterna Zentaris Announces Completion of Zoptrex Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017 77
Jan 04, 2017: Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen 78
Other Significant Developments 79
May 08, 2018: Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeterna Zentaris Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Aeterna Zentaris Enters into Agreement with EMD Serono 14
Aeterna Zentaris Enters into Co-Promotion Agreement with Ascend Therapeutics for EstroGel and Macrilen 15
Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 16
Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 17
Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 18
Rafa Labs Enters into Licensing Agreement with Aeterna Zentaris 19
Orient EuroPharma Enters into Licensing Agreement with Aeterna Zentaris 20
Aeterna Zentaris Enters into Option Agreement to License AEZS-120 Product 21
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 22
Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 23
Aeterna Zentaris Plans to Raise up to USD50 Million in Public Offering of Shares 24
Aeterna Zentaris Raises USD7.6 Million in Private Placement of Units 25
Aeterna Zentaris Raises USD16.7 Million in Public Offering of Shares and Warrants 26
Aeterna Zentaris Raises USD37 Million in Public Offering of Shares and Warrants 28
Aeterna Zentaris Files Registration Statement For Public Offering Of Shares For US$50 Million 30
Aeterna Zentaris Completes Public Offering Of Units For US$13.2 Million 31
AEterna Zentaris Completes Public Offering Of Units For US$15 Million 32
AEterna Zentaris Completes Private Placement Of Units For US$7.8 Million 34
AEterna Zentaris Announces Public Offering Of Shares For US$4.6 Million 35
Aeterna Zentaris Completes Public Offering Of Units For US$17 Million 36
Aeterna Zentaris Completes Second Tranche Of Public Offering Of Common Stock For US$2 Million 37
Aeterna Zentaris Inc, Key Competitors 38
Aeterna Zentaris Inc, Key Employees 39
Aeterna Zentaris Inc, Subsidiaries 40
List of Figures
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11